Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620688 | 0.84 | ERN1 (0.41) | ERN1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4988758 | 0.83 | ERN1 (0.53) | ERN1TRIM24TYRTRIM33ACHE | |
| SCHEMBL7480988 | 0.82 | ERN1 (0.44) | ERN1TRIM24TRIM33ALDH1A1PTPN1 | |
| SCHEMBL5155905 | 0.81 | ESR1 (0.49) | ERN1 | |
| SCHEMBL5150702 | 0.79 | ABL1 (0.45) | ALDH1A1ABL1ABCB1BCRPTPN1 | |
| SCHEMBL7487505 | 0.79 | ERN1 (0.50) | ERN1CA2 | |
| SCHEMBL5150242 | 0.76 | ALDH1A1 (0.45) | ERN1ALDH1A1ABCB1PTPN1NPC1 | |
| SCHEMBL29399003 | 0.75 | ERN1 (0.74) | ERN1TRIM24TYRTRIM33HDAC4 | |
| SCHEMBL19798735 | 0.75 | ERN1 (0.74) | ERN1TRIM24TYRTRIM33HDAC4 | |
| SCHEMBL7491658 | 0.73 | ERN1 (0.48) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1633699-B1 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1633699-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103941-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRA | ERN1 1356/4885TRIM24 2466/4885TYR 990/4885 |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, GPER1 | ERN1 1221/4885TRIM24 2141/4885TYR 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.